ストックスクリーナーアプリを入手
7.95
0.63%
0.05
アフターアワーズ：
7.95
Arvinas Inc (ARVN) 最新ニュース
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Gap UpWhat's Next? - MarketBeat
Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc. - MarketScreener
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade - MSN
Arvinas’s SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges - Investing.com
Analysts Set Expectations for Arvinas FY2026 Earnings - MarketBeat
ARVN: Arvinas' ARV-393 Shows Promise in Preclinical Lymphoma Stu - GuruFocus
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma - marketscreener.com
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV- - GuruFocus
Arvinas Unveils Promising ARV-393 Data at EHA Congress - TipRanks
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, - GlobeNewswire
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewswire Inc.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Arvinas (NASDAQ:ARVN) Stock Price Up 8.7%Here's Why - MarketBeat
Wedbush Predicts Arvinas' FY2026 Earnings (NASDAQ:ARVN) - MarketBeat
Wellington Management Group LLP Has $570,000 Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - WV News
Leerink Partnrs Has Strong Estimate for Arvinas Q2 Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Gap DownHere's Why - MarketBeat
Arvinas and Pfizer seek FDA approval for breast cancer drug By Investing.com - Investing.com South Africa
Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Leerink Partnrs - MarketBeat
Arvinas R&D President Ian Taylor Resigns - TipRanks
Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment - GuruFocus
Arvinas Announces Submission of New Drug Application to U.S. FDA - GuruFocus
Will Pfizer Walk Away From Arvinas After PROTAC Disappointment? - insights.citeline.com
Arvinas (ARVN) and Pfizer Submit FDA Application for Breast Canc - GuruFocus
Pfizer, Arvinas seek FDA nod for breast cancer therapy (ARVN) - Seeking Alpha
Arvinas stock rises on FDA submission with Pfizer By Investing.com - Investing.com Nigeria
Arvinas stock rises on FDA submission with Pfizer - Investing.com Australia
Arvinas and Pfizer seek FDA approval for breast cancer drug - Investing.com Australia
Arvinas announces submission of NDA to FDA for vepdegestrant - TipRanks
Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment - marketscreener.com
Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment | ARVN Stock News - GuruFocus
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - marketscreener.com
Arvinas Announces Submission of New Drug Application to - GlobeNewswire
What is Wedbush’s Forecast for Arvinas FY2026 Earnings? - Defense World
Q2 Earnings Forecast for Arvinas Issued By Leerink Partnrs - Defense World
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, AR - GuruFocus
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting | ARVN Stock News - GuruFocus
Arvinas, Inc. to Present Preclinical Data on ARV-393, an Investigational PROTAC BCL6 Degrader, at EHA Meeting 2025 - Nasdaq
Arvinas to Present Preclinical Data for PROTAC BCL6 - GlobeNewswire
Breakthrough PROTAC Technology Shows Efficacy Against 3 Types of Aggressive Lymphoma - Stock Titan
Arvinas (NASDAQ:ARVN) Earns Market Perform Rating from Leerink Partners - MarketBeat
Bank of America Corp DE Has $2.47 Million Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
H.C. Wainwright reaffirms buy rating on Arvinas stock after trial data - Investing.com Nigeria
Voloridge Investment Management LLC Buys Shares of 39,063 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):